ADVERTISEMENT
  • News
  • Technology
  • Culture
  • Entertainment
  • Sport
  • Travel
  • Music
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Monday, September 25, 2023
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Health&Beauty

Children’s asthma attacks reduced and lung function improved by Dupixent in a randomized phase 3 trial

The FINANCIAL by The FINANCIAL
October 13, 2020
in Health&Beauty
Reading Time: 3 mins read
A A
0
Share on FacebookShare on Twitter

The FINANCIAL — A pivotal Phase 3 trial of Dupixent® (dupilumab) met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. In a broad type 2 inflammatory asthma patient population, defined as having elevated eosinophils (EOS) or elevated fractional exhaled nitric oxide (FeNO), Dupixent added to standard of care significantly reduced asthma attacks (exacerbations) and improved lung function, as early as two weeks after the first dose, compared to standard of care alone. More than 90% of children in the trial had at least one concurrent type 2 inflammatory condition including atopic dermatitis and eosinophilic esophagitis. Safety results from the clinical trial were generally consistent with the known safety profile of Dupixent in patients aged 12 years and older with moderate-to-severe asthma.

ADVERTISEMENT

 “Children with uncontrolled moderate-to-severe asthma often struggle to breathe, largely because of their impaired lung function, and this can have a serious impact on their quality of life. It not only reduces their ability to participate in day-to-day activities, but can also take a huge emotional toll on the child and their family,” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. “Dupixent is the only biologic shown in a controlled Phase 3 trial to improve lung function in children, which is generally consistent with results seen in the adolescent and adult trials. These positive data are especially encouraging for younger children who are struggling to manage their uncontrolled asthma.”

Despite standard-of-care therapy such as inhaled corticosteroids (ICS), children with uncontrolled moderate-to-severe asthma continue to experience symptoms such as coughing, wheezing, and difficulty breathing, and are at risk of severe asthma attacks.
For these children, this often leads to frequent hospitalizations and emergency room visits requiring use of systemic corticosteroids which can carry significant risks when used long-term. Uncontrolled asthma can cause children to miss school, and can interfere with physical activity and routine tasks including walking up stairs and playing sports. In the U.S., there are approximately 75,000 children 6-11 years old with uncontrolled moderate-to-severe asthma, and many more of these children worldwide.

RelatedPosts

Clinical trial to test immune modulation strategy for hospitalized covid-19 patients begins

Researchers develop new method to identify potential stroke therapies

5 ways you can help a person experiencing a mental health crisis

Two Men Sentenced for $7.6 Million COVID Fraud Scheme

“Children with moderate-to-severe asthma live with a heavy and unpredictable disease burden. Even while taking maximum treatments including inhaled corticosteroids, they suffer from multiple asthma attacks each year that may require hospitalization,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. “These impressive Phase 3 data in children with asthma show Dupixent significantly reduced annual severe asthma attacks and also improved lung function consistently across patients with markers of type 2 inflammation.”

The primary endpoint assessed the annualized rate of severe asthma attacks in two primary pre-specified populations: patients with baseline blood EOS ≥300 cells/μl and patients with markers of type 2 inflammation (FeNO ≥20 ppb or EOS ≥150 cells/μl). Across these two patient groups respectively, those who added Dupixent (100 mg or 200 mg every two weeks, based on weight) to standard of care experienced:

  • Reduced rate of severe asthma attacks, with a 65% (p<0.0001) and 59% (p<0.0001) average reduction over one year compared to placebo (0.24 and 0.31 events per year for Dupixent vs. 0.67 and 0.75 for placebo, respectively)
  • Improved lung function at 12 weeks compared to baseline by 10.15 and 10.53 percentage points for Dupixent vs. 4.83 and 5.32 percentage points for placebo (least squares mean difference for Dupixent vs. placebo of 5.3 and 5.2 percentage points, p=0.0036 and p=0.0009), respectively, as measured by percent predicted FEV1 (FEV1pp). FEV1pp is a common endpoint in pediatric asthma trials to evaluate a patient’s change in lung function compared to their predicted lung function based on a number of factors including age, height and sex, to account for children’s growing lung capacity at different stages of development. This clinically meaningful improvement in lung function was observed as early as two weeks and was sustained for up to 52 weeks.

The safety results from the trial were generally consistent with the known safety profile of Dupixent in patients aged 12 years and older with moderate-to-severe asthma. Over one year, overall rates of adverse events were 83% for Dupixent and 80% for placebo. Adverse events that were most commonly observed with Dupixent versus placebo included injection site reactions (18% for Dupixent and 13% for placebo), viral upper respiratory tract infections (12% for Dupixent and 10% for placebo), and eosinophilia (6% for Dupixent and 1% for placebo).  

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), atopic dermatitis and eosinophilic esophagitis.

Tags: asthmaasthma attacksasthma in childrendupilumabdupilumab phase 3Dupixentsanof
ADVERTISEMENT
The FINANCIAL

The FINANCIAL

Related Posts

COVID-19 was third leading cause of death in the United States in both 2020 and 2021
Health&Beauty

Clinical trial to test immune modulation strategy for hospitalized covid-19 patients begins

by The FINANCIAL
September 22, 2023
0

A clinical trial has launched to test whether early intensive immune modulation for hospitalized COVID-19 patients with relatively mild illness...

Read more
Two Men Plead Guilty to $67M Medicare Fraud Scheme

Researchers develop new method to identify potential stroke therapies

September 22, 2023
In U.S., Smoking Dips, but Fewer Eating Healthy Since ’09

5 ways you can help a person experiencing a mental health crisis

September 11, 2023
COVID-19: Staying cyber secure

Two Men Sentenced for $7.6 Million COVID Fraud Scheme

September 9, 2023
Next Post

Ford updates America’s best-selling van with recreational vehicle and parcel delivery option packages

AOA issues warning against illegally sold contact lenses

AOA issues warning against illegally sold contact lenses

Delta publishes September Quarter financial results

Delta publishes September Quarter financial results

Please login to join discussion
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
Alejandro Betancourt López

Alejandro Betancourt López Credits Social Media With the Success of Hawkers

November 1, 2022
Find Social Security Number by Name Free

Find Social Security Number by Name Free

November 23, 2022
Employee Well-being as one of the main directions of corporate sustainability in the “Smart Capital Group” company

Employee Well-being as one of the main directions of corporate sustainability in the “Smart Capital Group” company

August 14, 2023
7 Vital Skills For A Successful Career In Finance

Survey of 249 Senior Enterprise Risk Executives Reveals Top 5 Emerging Risks in the Second Quarter of 2023

August 20, 2023
Facebook sued for $9bn in a tax court trial

6 Costly Yet Avoidable Digital Marketing Mistakes

August 11, 2023

Council fails to respond to restaurant nuisance complaints

September 22, 2023
COVID-19 was third leading cause of death in the United States in both 2020 and 2021

Clinical trial to test immune modulation strategy for hospitalized covid-19 patients begins

September 22, 2023

Goldman to Pay SEC $6 Million in Penalties for Providing Deficient Blue Sheet Data

September 22, 2023
Two Men Plead Guilty to $67M Medicare Fraud Scheme

Researchers develop new method to identify potential stroke therapies

September 22, 2023
65% say they always or often feel exhausted when thinking about politics

65% say they always or often feel exhausted when thinking about politics

September 22, 2023

Popular Last 24h

  • How to Check KRA Pin Using ID Number

    How to Check KRA Pin Using ID Number

    0 shares
    Share 0 Tweet 0
  • Alejandro Betancourt López Credits Social Media With the Success of Hawkers

    0 shares
    Share 0 Tweet 0
  • Unexpected High Demand – Tsavkisi Panorama Project in Tbilisi Completes One Year Earlier

    0 shares
    Share 0 Tweet 0
  • Credit quality concerns lead to higher provisions at US banks

    0 shares
    Share 0 Tweet 0
  • New Expression of Rolls-Royce Phantom Makes Its Debut in Georgia

    0 shares
    Share 0 Tweet 0
  • IMF Executive Board Concludes 2023 Article IV Consultation with the Republic of Estonia

    0 shares
    Share 0 Tweet 0
  • Home buyers gain breathing room with late-summer slowdown on the way

    0 shares
    Share 0 Tweet 0

LATEST POSTS

Council fails to respond to restaurant nuisance complaints

September 22, 2023
COVID-19 was third leading cause of death in the United States in both 2020 and 2021

Clinical trial to test immune modulation strategy for hospitalized covid-19 patients begins

September 22, 2023

Goldman to Pay SEC $6 Million in Penalties for Providing Deficient Blue Sheet Data

September 22, 2023
Two Men Plead Guilty to $67M Medicare Fraud Scheme

Researchers develop new method to identify potential stroke therapies

September 22, 2023
65% say they always or often feel exhausted when thinking about politics

65% say they always or often feel exhausted when thinking about politics

September 22, 2023
Mobile Banking and Beyond: The Ascendance of Mobile-First Fintech Software Solutions

Mobile Banking and Beyond: The Ascendance of Mobile-First Fintech Software Solutions

September 22, 2023
Why You Need to Have Emergency Savings

11 Money Management Tips For Financial Security

September 14, 2023

Inland waterway transport hits a decade low in 2022

September 14, 2023
EU produced 14.7 million bicycles in 2022

EU produced 14.7 million bicycles in 2022

September 14, 2023
Business investment rate stable at 23.0% in the euro area

A Rundown of the Latest Investment Trends in Health Care

September 14, 2023

LATEST INTERVIEWS

Lighting the path for sustainability in Georgia

Lighting the path for sustainability in Georgia

by The FINANCIAL
August 14, 2023
0

Toyota Plays a Crucial Role in Contributing to Georgia’s Zero Emissions Challenge

Toyota Plays a Crucial Role in Contributing to Georgia’s Zero Emissions Challenge

by The FINANCIAL
July 12, 2023
0

The Biltmore Tbilisi Hotel in Georgia’s key CSR projects aimed at creating a beneficial influence on the local community

The Biltmore Tbilisi Hotel in Georgia’s key CSR projects aimed at creating a beneficial influence on the local community

by The FINANCIAL
July 12, 2023
0

“EU membership might attract European banks and other financial institutions to enter Georgia”

“EU membership might attract European banks and other financial institutions to enter Georgia”

by The FINANCIAL
May 15, 2023
0

Main risks facing banks in 2023

Main risks facing banks in 2023

by The FINANCIAL
May 15, 2023
0

‘Russia cannot be treated as a reasonable and reliable trade partner

‘Russia cannot be treated as a reasonable and reliable trade partner

by The FINANCIAL
February 13, 2023
0

We should increase our joint efforts to assist the growing tech sector here in Georgia

We should increase our joint efforts to assist the growing tech sector here in Georgia

by The FINANCIAL
February 13, 2023
0

‘Georgia has much to offer to UK investors

‘Georgia has much to offer to UK investors

by The FINANCIAL
February 13, 2023
0

Newsletter

ADVERTISEMENT

GET IN TOUCH

E-mail your company news at:

news (at) financial.ge Letters to the Editor: editor (at) finchannel.com

Local Marketing contact:

(+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com

Requests from abroad:

(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com Contact video editor: E-mail: video (at) financial.ge

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.